基质金属蛋白酶26蛋白在非小细胞肺癌组织中的表达及其意义

背景与目的：基质金属蛋白酶26（matrix metalloproteinase-26，MMP-26）与多种恶性肿瘤的发生、发展及转移相关。本实验通过检测MMP-26蛋白在浸润性非小细胞肺癌（non-small cell lung cancer，NSCLC）、浸润前肺癌和正常肺组织中的表达．探讨MMP-26在NSCLC发生发展中的作用及与预后的关系。方法：采用免疫组织化学（SP）法，分别检测72例NSCLC、14例非典型增生和10例正常肺组织中MMP-26蛋白的表达。结果：MMP-26蛋白高表达率在正常肺组织中为0（0／10），在非典型增生巾为14．3％（2／14），在NSCLC中为59．7％（43／72）。MMP-26蛋白在NSCLC中的表达高于在非典型增生及正常肺组织中（P〈0．01），在非典型增生中高于正常肺组织中，但二者差异无统计学意义（P〉0．05）。MMP-26蛋白表达与NSCLC分期（P〈0．05）和淋巴结转移有关（P〈0．05），而与患者年龄、性别以及肿瘤大小、分化无关（P〉0．05）。Cox比例风险模型进行多因素生存分析显示：MMP-26表达和临床分期是有意义的NSCLC预后指标（P〈0．05）。MMP-26蛋白高表达的NSCLC患者无复发生存期和总生存期低于阴性表达的患者（分别为log-rank=19．34、23．2，P〈0．001、0．001）。结论：MMP-26蛋白高表达与NSCLC发生、淋巴结转移、临床分期及预后相关，有可能作为判断NSCLC进展和预测预后的一项指标。

Expression and clinical significance of matrix metalIoproteinase(MMP)-26 protein in non-small cell lung cancer

Background and Objective： Matrix metalloproteinase（MMP）-26 has been implicated in genesis, progression, invasion and metastasis of several types of human cancers. This study was to investigate the expression of MMP- 26 protein in invasive non-small cell lung cancer （NSCLC）, pre-invasive lung cancer and normal lung tissues, thus to explore the role of MMP-26 in the progression and prognosis of NSCLC. Methods： SP immunohistochemistry was used to measure the expression of MMP-26 protein in 72 specimens of NSCLC, 14 specimens of atypical hyperplasia and 10 specimens of normal lung tissues. Results： The high expression rate of MMP-26 was 0 （0/10） in normal lung tissues, 14.3%（2/14） in atypical hyperplasia and 59.7%（43/72） in NSCLC. The expression rate of MMP-26 protein was significantly higher in NSCLC than in atypical hyperplasia and normal lung tissues （P〈0.01）; the expression was higher in atypical hyperplasia than in normal lung tissues, but the difference was not significant（P〉0.05）. The high expression rate of MMP- 26 protein was significantly correlated to stage （P〈0.05） and lymph node metastasis（P 〈0.05 ）, but not to age, gender, tumor size and differentiation （P〉0.05）. Multivariate analysis showed that MMP-26 and stage were independent prognostic factors of NSCLC （P〈0.05）. The disease-free survival and overall survival were shorter in NSCLC patients with high expression of MMP-26 than in those with low expression of MMP-26 （Iog-rank=19.34 and 23.2, both P〈0.001）. Conclusion： High expression of MMP-26 protein is correlated to carcinogenesis, lymph node metastasis, clinical stage and prognosis of NSCLC. Therefore, MMP-26 may be served as a tumor marker in monitoring progression and predicting prognosis of NSCLC.